{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:13Z","timestamp":1753892053173,"version":"3.41.2"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Mental disorders can have a significant impact on patients\u2019 life, including economic, social and individual consequences, and psychotropic medication is essential to treat these conditions. Psychotropic drug utilization studies contribute to a clearer picture of the management of these conditions. Data published from Romania on this topic is limited. The present study aims to characterize the utilization patterns of anxiolytics, antidepressants (ADs), and antipsychotics (APs) in Romania during 1998\u20132018.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Drug utilization data were provided by Management Center for Documentation, Information and Marketing (CEGEDIM) Romania and quantitative data for each psychotropic medicine were converted to total defined daily doses (DDDs) and to DDD\/1000inhabitants\/day (DDD\/TID). The total use of medicines in DDD\/TID was computed in order to obtain the drug utilization 90% (DU90%) segment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> An increasing trend in total utilization of psychotropic medicines in Romania started in 2004. Anxiolytics use was predominant until 2013 and the yearly anxiolytic use over the entire study period remained between 10 and 15\u00a0DDD\/TID. Diazepam lost popularity over time in detriment of the utilization of other anxiolytic benzodiazepines, such as alprazolam and lorazepam. ADs utilization markedly increased during the study period (the average annual growth rate was 13.66% starting 1999). Selective serotonin reuptake inhibitors (SSRIs) became present on the 2008 DU90% and was the dominant class of ADs, with sertraline being the most prescribed, followed by escitalopram and paroxetine. APs utilization showed an increasing trend from 2003 until 2018. Atypical APs became present on the 2008 DU90%, while typical APs were no longer included in the 2018 DU90%. Among atypical APs, olanzapine was the main agent prescribed, and starting 2010 was followed by quetiapine and risperidone. The uptake of APs long-acting formulations became more evident during the last analyzed years (2015\u20132018).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We observed an increasing utilization of APs and a more prominent increase in ADs utilization in Romania during 1998\u20132018. The anxiolytic prescribing remained nearly stable during this time. Further research can bring more information on the various factors influencing psychotropic utilization in Romania.<\/jats:p>","DOI":"10.3389\/fphar.2023.1157231","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T05:39:32Z","timestamp":1679895572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Utilization of psychotropic medicines in Romania during 1998\u20132018"],"prefix":"10.3389","volume":"14","author":[{"given":"Irina","family":"Iaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Bucsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Farcas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Pop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamaria","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Armean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Brumboiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliviu","family":"Vostinaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mogosan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00228-014-1676-z","article-title":"Antidepressant prescribing in five European countries: Application of common definitions to assess the prevalence, clinical observations, and methodological implications","volume":"70","author":"Abbing-Karahagopian","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000493015","article-title":"Benzodiazepines: A valuable tool in the management of cardiovascular conditions","volume":"87","author":"Balon","year":"2018","journal-title":"Psychother. Psychosom."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e14770","DOI":"10.1111\/ijcp.14770","article-title":"Drug utilisation study of antidiabetic medication during 2012-2019 in Romania","volume":"75","author":"Bucsa","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1007\/s11096-019-00915-2","article-title":"Outpatient benzodiazepine utilization in Croatia: Drug use or misuse","volume":"41","author":"Dela\u0161 A\u017edaji\u0107","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8612","DOI":"10.3390\/ijerph17228612","article-title":"The use of antidepressants, anxiolytics, sedatives and hypnotics in Europe: Focusing on mental health care in Portugal and prescribing in older patients","volume":"17","author":"Estrela","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B8","unstructured":"Eurostat database2022"},{"key":"B9","unstructured":"EMA confirms positive benefit-risk for antidepressant Valdoxan\/Thymanax (agomelatine)2014"},{"key":"B10","unstructured":"Health systems in transition: Romania, health system review2016"},{"key":"B11","unstructured":"State of health in the EU. Romania: Country health profile2021"},{"key":"B12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jad.2019.02.010","article-title":"Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators","volume":"249","author":"Forns","year":"2019","journal-title":"J. Affect Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1586\/14737167.2016.1158649","article-title":"Differences in utilization rates between commercial and administrative databases: Implications for future health-economic and cross-national studies","volume":"16","author":"Garuoliene","year":"2016","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2217\/cer-2018-0132","article-title":"Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence","volume":"8","author":"Godman","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/cer.13.75","article-title":"Generic atypical antipsychotic drugs in Belgium: Their influence and implications","volume":"2","author":"Godman","year":"","journal-title":"J. Comp. Eff. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/14737167.2013.820956","article-title":"Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries","volume":"13","author":"Godman","year":"","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40258-013-0037-x","article-title":"Changes in the utilization of venlafaxine after the introduction of generics in Sweden","volume":"11","author":"Godman","year":"","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/jcm7020017","article-title":"Benzodiazepines I: Upping the care on downers: The evidence of risks, benefits and alternatives","volume":"7","author":"Guina","year":"2018","journal-title":"J. Clin. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e66455","DOI":"10.1371\/journal.pone.0066455","article-title":"Antidepressant utilization and suicide in europe: An ecological multi-national study","volume":"8","author":"Gusm\u00e3o","year":"2013","journal-title":"PLoS ONE"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: A study in 16 countries, 2005-2014","volume":"27","author":"Halfdanarson","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/bcp.13945","article-title":"Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016","volume":"85","author":"Hojlund","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.24869\/psyd.2019.457","article-title":"The prevalence and burden of mental and substance use disorders in Romania: Findings from the Global Burden of Disease Study 2016","volume":"31","author":"Iovu","year":"2019","journal-title":"Psychiatr. Danub."},{"key":"B24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.eurpsy.2010.05.005","article-title":"Prescribing practices in psychiatric hospitals in Eastern Europe","volume":"26","author":"Jordanova","year":"2011","journal-title":"Eur. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.20471\/dec.2020.56.02.05","article-title":"Antipsychotic drugs consumption in primary health care in Albania during the 2004 - 2016 period","volume":"56","author":"Kakariqi","year":"2020","journal-title":"Arch. psychiatry Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1192\/bjp.bp.114.156786","article-title":"Antidepressant use in 27 European countries: Associations with sociodemographic, cultural and economic factors","volume":"207","author":"Lewer","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e004221","DOI":"10.1136\/bmjopen-2013-004221","article-title":"An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making","volume":"4","author":"McNaughton","year":"2014","journal-title":"BMJ Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.focus.20200051","article-title":"Contrasting typical and atypical antipsychotic drugs","volume":"19","author":"Meltzer","year":"2021","journal-title":"Focus"},{"volume-title":"European anti-depression day october 1, 2019. Situation analysis","year":"2019","key":"B29"},{"key":"B30","unstructured":"Nomenclature of medicines for human use2022"},{"key":"B31","unstructured":"Therapeutic protocols2018"},{"key":"B32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12888-020-02538-8","article-title":"Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain","volume":"20","author":"Orrico-Sanchez","year":"2020","journal-title":"BMC Psychiatry"},{"key":"B33","first-page":"415","article-title":"Trends in the outpatient utilization of antipsychotic drugs in the city of zagreb in the ten-year period as a tool to assess drug prescribing rationality","volume":"28","author":"Poli\u0107-Vi\u017eintin","year":"2016","journal-title":"Psychiatr. Danub"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40360-016-0081-x","article-title":"Potentially inappropriate medications in elderly ambulatory and institutionalized patients: An observational study","volume":"17","author":"Primejdie","year":"2016","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","journal-title":"J. Sleep. Res."},{"key":"B36","unstructured":"Clinical guidelines2018"},{"key":"B37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/9781118949740.ch6","article-title":"Measurement units of drug utilization","volume-title":"Drug utilization research: Methods and applications","author":"Salvesen Blix","year":"2016"},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0004867412466595","article-title":"Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011","volume":"47","author":"Stephenson","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3238\/arztebl.2018.0611","article-title":"The diagnosis and treatment of anxiety disorders","volume":"115","author":"Str\u00f6hle","year":"2018","journal-title":"Dtsch. Arzteblatt Int."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00228-019-02654-9","article-title":"Antipsychotic utilization patterns among patients with schizophrenic disorder: A cross-national analysis in four countries","volume":"75","author":"Sultana","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/08039488.2020.1854853","article-title":"Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences","volume":"75","author":"Taipale","year":"2020","journal-title":"Nord. J. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/healthcare10071342","article-title":"Trends and geographic variabilities in benzodiazepines prescription in primary care to older adults: A 3-year population-based ecological study in Portugal","volume":"10","author":"Tavares","year":"2022","journal-title":"Healthc. (Basel)"},{"key":"B44","unstructured":"Decision no. 1915\/2006 approving the Methodological Norms for the application of the provisions of Law no. 339\/2005 on the legal regime of narcotic and psychotropic plants, substances and preparations2006"},{"key":"B45","unstructured":"Framework Contract regulating the conditions for the provision of medical assistance, medicines and medical devices within the social health insurance system for the years 2018-20192018"},{"volume-title":"Health at a glance: Europe 2018","year":"2018","key":"B46"},{"key":"B47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1186\/s12889-020-08984-z","article-title":"Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015","volume":"20","author":"Torres-Bondia","year":"2020","journal-title":"BMC Public Health"},{"key":"B48","first-page":"33","volume-title":"Ghid de farmacoterapie \u00een tulburarea depresiv\u0103 major\u0103","author":"Udri\u0219toiu","year":"2010"},{"key":"B49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/pds.852","article-title":"Drug utilisation 90% profiles--a useful tool for quality assessment of prescribing in primary health care in Stockholm","volume":"12","author":"Wettermark","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf."},{"volume-title":"Buspirone","year":"2022","author":"Wilson","key":"B50"},{"key":"B51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/11318840-000000000-00000","article-title":"Influence of patient co-payments on atypical antipsychotic choice in Poland: Implications once generic atypicals are available","volume":"9","author":"Wladysiuk","year":"2011","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B52","unstructured":"Collaborating Centre for durg Statistics methodology ATC\/DDD Index2022"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1157231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T05:39:53Z","timestamp":1679895593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1157231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":49,"alternative-id":["10.3389\/fphar.2023.1157231"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1157231","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"article-number":"1157231"}}